{
      "Rank": 372,
      "Acronym": [
            "IDUNN"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Participants will receive MC0518 1-2 million cells/ kilogram infusions (based on body weight at the Screening Visit) once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.",
            "Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), everolimus, and ruxolitinib (RUX)."
      ],
      "ArmGroupInterventionName": [
            "Biological: MC0518",
            "Biological: BAT"
      ],
      "ArmGroupLabel": [
            "MC0518",
            "Best Available Therapy (BAT)"
      ],
      "ArmGroupType": [
            "Experimental",
            "Active Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04629833"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The primary purpose of this trial is to demonstrate the superiority of MC0518 compared to the first used best available therapy (BAT) with respect to overall response rate (ORR) in adult and adolescent participants with steroid-refractory acute graft-versus-host disease (SR-aGvHD) at Day 28."
      ],
      "BriefTitle": [
            "Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "December 31, 2025"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Steroid-refractory Acute Graft-versus-host Disease"
      ],
      "ConditionAncestorId": [
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC20",
            "All",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Immune System Diseases",
            "All Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Graft Versus Host Disease",
            "Graft Versus Host Disease",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafId": [
            "M8341",
            "M9352",
            "T2832",
            "T170"
      ],
      "ConditionBrowseLeafName": [
            "Graft vs Host Disease",
            "Immune System Diseases",
            "Homologous Wasting Disease",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "high",
            "high"
      ],
      "ConditionMeshId": [
            "D000006086"
      ],
      "ConditionMeshTerm": [
            "Graft vs Host Disease"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nParticipant had a previous allogeneic HSCT as indicated for non-malignant (including inborn errors of metabolism, primary immunodeficiencies, haemoglobinopathies, and bone marrow failure syndromes) or haematological malignant disease, irrespective of human leukocyte antigen match\nParticipant has been clinically diagnosed with Grade II to IV aGvHD at the Screening Visit\nParticipant has experienced failure of previous first-line aGvHD treatment (ie, SR-aGvHD), defined as: a) aGvHD progression within 3 to 5 days of therapy onset with >= 2 mg/kg/day of prednisone equivalent or b) failure to improve within 5 to 7 days of treatment initiation with >= 2 mg/kg/day of prednisone equivalent or c) incomplete response after > 28 days of immunosuppressive treatment including at least 5 days with >= 2 mg/kg/day of prednisone equivalent\nParticipant has an estimated life expectancy > 28 days at the Screening Visit\nMale or female participant who is >= 12 years of age at the Screening Visit\n\nExclusion Criteria:\n\nParticipant has overt relapse or progression or persistence of the underlying disease at the Screening Visit\nParticipant has received the last HSCT for a solid tumour disease\nParticipant has GvHD overlap syndrome at the Screening Visit\nParticipant has received systemic first-line treatment for aGvHD other than steroids and a prophylaxis with other than calcineurin inhibitors, anti-thymocyte globulin (ATG), mycophenolate mofetil (MMF), methotrexate (MTX), and or cyclophosphamide before the Screening Visit\nParticipant has a known pregnancy (as confirmed by a positive pregnancy test at the Screening Visit) and or is breastfeeding at the Screening Visit\nParticipant has received treatment with any other investigational agent within 30 days or 5 half-lives (whichever is longer) before the Screening Visit (compliance to be confirmed for the period between the Screening Visit and the Baseline Visit at the Baseline Visit)."
      ],
      "EnrollmentCount": [
            "210"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "MC0518",
            "Best Available Therapy (BAT)"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "ANeo",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Antineoplastic Agents",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M11280",
            "M255",
            "M3431"
      ],
      "InterventionBrowseLeafName": [
            "Mycophenolic Acid",
            "Everolimus",
            "Antilymphocyte Serum"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "MC0518 will be intravenously infused immediately after thawing.",
            "BAT including MMF, ECP, ATG, everolimus, and RUX will be administered based on Investigator's decision."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "MC0518",
            "BAT"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Biological"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "June 8, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "June 7, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "medac GmbH"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Grenoble",
            "Lille",
            "Nice",
            "Pierre Benite Cedex",
            "Rennes",
            "Toulouse",
            "Vandoeuvre les Nancy",
            "Munich",
            "W\u00fcrzburg",
            "Frankfurt am Main",
            "Hannover",
            "M\u00fcnster",
            "Essen",
            "Koeln",
            "Dresden",
            "Leipzig",
            "Jena",
            "Jena",
            "Berlin",
            "Bonn",
            "Essen",
            "Frankfurt",
            "Freiburg",
            "Mainz",
            "Mannheim",
            "Tuebingen",
            "Wroc\u0142aw",
            "Barcelona",
            "Barcelona",
            "Barcelona",
            "Barcelona",
            "Barcelona",
            "Madrid",
            "Madrid",
            "Valencia",
            "Huddinge"
      ],
      "LocationContactEMail": [
            "cebulabois@chu-grenoble.fr",
            "Ibrahim.YAKOUBAGHA@CHRU-LILLE.FR",
            "loschi.m@chu-nice.fr",
            "helene.labussiere-wallet@chu-lyon.fr",
            "Huynh.Anne@iuct-oncopole.fr",
            "m.daveni-piney@chru-nancy.fr",
            "mareike.verbeek@tum.de",
            "kraus_s3@klinik-uni-wuerzburg.de",
            "g.bug@em.uni-frankfurt.de",
            "Beutel.Gernot@mh-hannover.de",
            "matthias.stelljes@ukmuenster.de",
            "Rudolf.Trenschel@uk-essen.de",
            "udo.holtick@uk-koeln.de",
            "friedrich.stoelzel@uniklinikum-dresden.de",
            "georg-nikolaus.franke@medizin.uni-leipzig.de",
            "inken.hilgendorf@med.uni-jena.de",
            "bernd.gruhn@med.uni-jena.de",
            "johannes.schulte@charite.de",
            "tobias.holderried@ukbonn.de",
            "o.Basu@uk-essen.de",
            "peter.bader@kgu.de",
            "robert.zeiser@uniklinik-freiburg.de",
            "eva.wagner@unimedizin-mainz.de",
            "stefan.klein@umm.de",
            "wolfgang.bethge@med.uni-tuebingen.de",
            "krzysztof.kalwak@gmail.com",
            "gorti@vhio.net",
            "amussetti@iconcologia.net",
            "atorrent@iconcologia.net",
            "jljimenez@salud.madrid.org",
            "rduarte.work@gmail.com",
            "carlos.solano@uv.es",
            "stephan.mielke@ki.se"
      ],
      "LocationContactName": [
            "Claude-Eric Bulabois",
            "Ibrahim Yakoub Agha",
            "Michael Loschi",
            "Helene Labussiere-Wallet",
            "Anne Huynh",
            "Maud D'Aveni-Piney",
            "Mareike Verbeek",
            "Sabrina Kraus",
            "Gesine Bug",
            "Gernot Beutel",
            "Matthias Stelljes",
            "Rudolf Trenschel",
            "Udo Holtick",
            "Friedrich Stolzel",
            "Georg-Nikolaus Franke",
            "Inken Hilgendorf",
            "Bernd Gruhn",
            "Johannes Schulte",
            "Tobias Holderried",
            "Oliver Basu",
            "Peter Bader",
            "Robert Zeiser",
            "Eva Wagner-Drouet",
            "Stefan Klein",
            "Wolfgang Bethge",
            "Krzysztof Kalwak",
            "Guillermo Orti",
            "Alberto Mussetti",
            "Anna Torrent Catarineu",
            "Francisco Javier Lopez Jimenez",
            "Rafael Duarte Palomino",
            "Carlos Solano",
            "Stephan Mielke"
      ],
      "LocationContactPhone": [
            "33-476 76 56 63",
            "33-3-20445713",
            "33-33-0492035558",
            "33-33-478862210",
            "33-5-31-15-61-89",
            "33-383-153-282",
            "49-89-41405336",
            "4993120140411",
            "49--69--6301",
            "49-511-532-3020",
            "49-251-8352801",
            "49201-723",
            "+49 (0) 221 478 85523",
            "+49 351 458 19475",
            "493419713842",
            "49-3641-9-324513",
            "49-3641-9329574",
            "49-030-450 566 132",
            "49-228-287 17233",
            "49-201-723-5165",
            "49-69 6301 7541",
            "49-076-127034580",
            "49-6131-172712",
            "49-621-383",
            "4970712983176",
            "48-4871-7332840",
            "+34 93 274 61 00",
            "+34 667 069 283",
            "34-93-497-89-87",
            "34-91-3368637",
            "34-911916303",
            "34-96-1973838",
            "+46-0725955987"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact"
      ],
      "LocationCountry": [
            "France",
            "France",
            "France",
            "France",
            "France",
            "France",
            "France",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Poland",
            "Spain",
            "Spain",
            "Spain",
            "Spain",
            "Spain",
            "Spain",
            "Spain",
            "Spain",
            "Sweden"
      ],
      "LocationFacility": [
            "CHU de Grenoble Hopital Albert Michallon",
            "CHRU Lille- Hopital Claude Huriez",
            "CHU de Nice Hopital Archet 1",
            "Centre Hospitalier Lyon Sud Pavillon Marcel Berard 1G",
            "Rennes",
            "Centre Hospitalier Universitaire CHU de Toulouse",
            "Hopitaux De Brabois",
            "Klinikum rechts der Isar",
            "Universitaetsklinikum Wuerzburg - Medizinische Klinik und Poliklinik II - Zentrum fuer Allogene Blutstammzelltransplantation",
            "Klinikum der Johann Wolfgang Goethe-Universitaet - Frankfurt am Main",
            "Medizinische Hochschule Hannover",
            "Universitatsklinikum Muenster",
            "Universitaet Duisburg-Essen - Universitaetsklinikum Essen - Klinik fuer Knochenmarktransplantation (KMT)",
            "Uniklinik Koeln",
            "Universitatsklinikum Carl Gustav Carus Dresden",
            "Selbststandige Abteilung fur Hamatologie und Internistische Onkologie",
            "Universitaetsklinikum Jena",
            "Universitatsklinikum Jena",
            "Charit Universitaetsmedizin Berlin",
            "University Hospital Bonn, Medizinische Klinik III",
            "Universitaetsklinikum Essen",
            "Klinikum der Johann Wolfgang Goethe",
            "Universitatklinikum Freiburg",
            "University Medical Center Mainz",
            "Universit\u00c3\u00a4tsklinikum Mannheim",
            "University Hospital Tuebingen Medical Center",
            "Department of Pediatric Hematology, Oncology and BMT, Wroclaw Medical University",
            "Hospital Universitario Vall dHebron",
            "Barcelona",
            "Institut Catal dOncologia",
            "Barcelona",
            "Hospital Germans Trias i Pujol",
            "Hospital Universitario Ramon y Cajal",
            "Hospital Puerta De Hierro",
            "Hospital Clinico Universitario de Valencia",
            "Center for Allogeneic Stem Cell Transplantation and Cell Therapy (CAST), Karolinska Universitetssjukhuset Huddinge"
      ],
      "LocationState": [
            "Bavaria",
            "Bavaria",
            "Hessen",
            "Niedersachsen",
            "Nordrhein-Westfalen",
            "North Rhine-Westphalia",
            "North Rhine-Westphalia",
            "Sachsen",
            "Saxony",
            "Th\u00fcringen",
            "Th\u00fcringen",
            "Dolnoslaskie"
      ],
      "LocationStatus": [
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Withdrawn",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Not yet recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Withdrawn",
            "Recruiting",
            "Withdrawn",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Not yet recruiting"
      ],
      "LocationZip": [
            "38700",
            "59000",
            "06200",
            "69630",
            "35000",
            "31059",
            "54511",
            "81675",
            "97080",
            "60590",
            "30625",
            "48149",
            "45147",
            "50937",
            "01307",
            "04103",
            "07740",
            "07747",
            "13353",
            "53127",
            "45147",
            "60590",
            "79106",
            "55131",
            "68167",
            "72076",
            "50-556",
            "08035",
            "08041",
            "08908",
            "08909",
            "08916",
            "28034",
            "28222",
            "46010",
            "14157"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "12 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Randomised, Open-label, Multicentre, Phase 3 Trial of First-line Treatment With Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects With Steroid-refractory Acute Graft-versus-host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial)"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "medac GmbH"
      ],
      "OrgStudyId": [
            "MC-MSC.1/aGvHD"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Syneos Health"
      ],
      "OverallOfficialName": [
            "Jolanda Neele"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 3"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "January 28, 2024"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "OR is defined as complete response (CR) or partial response (PR) at Day 28 relative to aGvHD status at baseline. CR is defined as resolution of aGvHD in all involved organs. PR is defined as improvement in 1 stage in 1 or more organs involved with aGvHD symptoms without progression in others. Number of participants with OR will be reported."
      ],
      "PrimaryOutcomeMeasure": [
            "Overall Response (OR)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Day 28"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "FFTF is defined as death, relapse or progression of the underlying disease, or addition or change to any further systemic immunosuppressive aGvHD therapy. Number of participants with FFTF will be reported.",
            "Overall survival is defined as the time from randomization to the date of death due to any cause.",
            "Number of participants with aGvHD response will be reported. aGvHD response will be categorized as OR (CR + PR), CR, PR, and NR. NR is defined as the absence of CR or PR.",
            "aGvHD grades: Grade 0- no organ involvement (ie, Stage 0 skin, Stage 0 liver, and Stage 0 GI); Grade I-Stage 1 - 2 skin without liver/GI involvement; Grade II- Stage 3 skin and / or Stage 1 liver and / or Stage 1 GI; Grade III- Stage 2 - 3 liver and / or Stage 2 - 3 GI; Grade IV- Stage 4 skin and / or Stage 4 liver and/or Stage 4 GI.",
            "Time to response is defined as the time from the date of the first treatment administration to the date of response.",
            "Duration is calculated from time from the first OR (CR or PR) until the time point of no aGvHD response in comparison to baseline.",
            "Best OR is defined as the achievement of an OR at any time point up to and including Day 28. Number of participants with best OR will be reported.",
            "The cumulative dose of steroids given for SR-aGvHD per kg of body weight from baseline until Day 60 and until Visit Month 24 will be analyzed.",
            "Number of participants with cGvHD will be reported.",
            "Time to cGvHD is defined as the time between the last day of haematopoietic stem cell transplantation (HSCT) to the first episode of cGvHD.",
            "Number of participants with GF will be reported.",
            "Number of participants with relapse or progression in participants with underlying malignant disease will be reported.",
            "Time to relapse or progression in participants with underlying malignant disease will be reported.",
            "EFS is defined as the time from the date of randomization to the date of the event. An event is defined as GF, relapse or progression of the underlying disease, or death due to any cause.",
            "NRM is defined as the time from the date of randomisation to the date of the event. An event is defined as death without previous relapse or progression of the underlying disease.",
            "Severity will be graded based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening consequences; urgent intervention indicated; Grade 4- Death related to the AE.",
            "The Karnofsky performance score (KPS), which is reported on an ordinal scale from 0 to 100, provides a rough measure of the participant's well-being, including their ability to conduct activities of daily living and functional capacity. Higher score indicates normal, no complaints and no evidence of disease.",
            "A Lansky score (recipient age greater than or equal to [>=] 1 years and less than [<] 16 years) will be recorded pre-treatment and measured serially at regular intervals after treatment. The score is a standard performance score that measures overall function of the child with a scale range from 0 to 100. Higher score indicates full activeness.",
            "EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health \"TODAY\". Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health).",
            "EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine).",
            "The FACT-BMT questionnaire was designed to measure the quality of life in subjects undergoing bone marrow (BM) transplantation. It consists of the following categories of assessment: physical well-being, social / family well-being, emotional well-being, functional well-being, and additional miscellaneous concerns that the subject may have concerning their healthcare, persons involved in their life, and other emotions and incapabilities. Score ranges from 0-164, with higher score indicating better quality of life."
      ],
      "SecondaryOutcomeMeasure": [
            "Freedom from Treatment Failure (FFTF)",
            "Overall Survival",
            "Acute Graft-versus-host Disease (aGvHD) Response",
            "Change from Baseline in aGvHD Grades",
            "Time to Response",
            "Duration of Response",
            "Best Overall Response (OR)",
            "Cumulative Dose of Steroids for SR-aGvHD per Kilogram (kg) of Body Weight",
            "Number of Participants with Chronic Graft-versus-host Disease (cGvHD)",
            "Time to Chronic Graft-versus-host Disease (cGvHD)",
            "Number of Participants with Graft Failure (GF)",
            "Number of Participants with Relapse or Progression in Participants with Underlying Malignant Disease",
            "Time to Relapse or Progression in Participants with Underlying Malignant Disease",
            "Event-free survival (EFS)",
            "Non-relapse Mortality (NRM)",
            "Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs)",
            "Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs) by Severity",
            "Change from Baseline in Performance score based on Karnofsky scale (recipient age >= 16 years)",
            "Change from Baseline in Performance score based on Lansky Scale",
            "Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Health Status Index (HSI)",
            "Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Visual Analogue Scale (VAS)",
            "Change from Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Score"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Up to 6 months",
            "Up to Month 24",
            "Days 28, 60, 100 and 180",
            "Baseline and Days 8, 15, 22, 28, 60, 100 and 180",
            "Up to Month 24",
            "Up to Month 24",
            "Up to Day 28",
            "Up to Day 60 and Month 24",
            "Day 60 to Month 24",
            "Day 60 to Month 24",
            "Up to Month 24",
            "Up to Month 24",
            "Up to Month 24",
            "Up to Month 24",
            "Up to Month 24",
            "Until Day 60 or until 30 days after last administration of trial treatment, whichever is later (Up to Month 24)",
            "Until Day 60 or until 30 days after last administration of trial treatment, whichever is later (Up to Month 24)",
            "Baseline, Days 8, 15, 22, 28, 60 and 100",
            "Baseline, Days 8, 15, 22, 28, 60 and 100",
            "Baseline, Days 28, 60, 100 and 180",
            "Baseline, Days 28, 60, 100 and 180",
            "Baseline, Days 28, 60, 100 and 180"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "August 16, 2021"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "June 2022"
      ],
      "StdAge": [
            "Child",
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "November 16, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "November 9, 2020"
      ],
      "StudyFirstSubmitQCDate": [
            "November 9, 2020"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}